» Articles » PMID: 34205470

The Transplantation Resistance of Type II Diabetes Mellitus Adipose-Derived Stem Cells Is Due to G6PC and IGF1 Genes Related to the FoxO Signaling Pathway

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Jul 2
PMID 34205470
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

In cases of patients with rapidly progressive diabetes mellitus (DM), autologous stem cell transplantation is considered as one of the regenerative treatments. However, whether the effects of autonomous stem cell transplantation on DM patients are equivalent to transplantation of stem cells derived from healthy persons is unclear. This study revealed that adipose-derived mesenchymal stem cells (ADSC) derived from type II DM patients had lower transplantation efficiency, proliferation potency, and stemness than those derived from healthy persons, leading to a tendency to induce apoptotic cell death. To address this issue, we conducted a cyclopedic mRNA analysis using a next-generation sequencer and identified and , genes related to the FoxO signaling pathway, as the genes responsible for lower performance. Moreover, it was demonstrated that the lower transplantation efficiency of ADSCs derived from type II DM patients might be improved by knocking down both and genes. This study clarified the difference in transplantation efficiency between ADSCs derived from type II DM patients and those derived from healthy persons and the genes responsible for the lower performance of the former. These results can provide a new strategy for stabilizing the quality of stem cells and improving the therapeutic effects of regenerative treatments on autonomous stem cell transplantation in patients with DM.

Citing Articles

The Diurnal Variation in Mitochondrial Gene in Human Type 2 Diabetic Mesenchymal Stem Cell Grafts.

Horiguchi M, Yoshihara K, Mizukami Y, Watanabe K, Tsurudome Y, Ushijima K Int J Mol Sci. 2025; 26(2.

PMID: 39859433 PMC: 11765740. DOI: 10.3390/ijms26020719.


Circadian Rhythms of Clock Genes After Transplantation of Mesenchymal Stem Cells with Type 2 Diabetes Mellitus.

Horiguchi M, Yoshihara K, Watanabe K, Tsurudome Y, Mizukami Y, Ushijima K Int J Mol Sci. 2024; 25(23).

PMID: 39684854 PMC: 11641841. DOI: 10.3390/ijms252313145.


Optimizing Mesenchymal Stem Cells for Regenerative Medicine: Influence of Diabetes, Obesity, Autoimmune, and Inflammatory Conditions on Therapeutic Efficacy: A Review.

Przywara D, Petniak A, Gil-Kulik P Med Sci Monit. 2024; 30:e945331.

PMID: 39154207 PMC: 11340262. DOI: 10.12659/MSM.945331.


and genes cause transplantation resistance of adipose-derived mesenchymal stem cells in type 1 diabetes mellitus.

Horiguchi M, Tsurudome Y, Ushijima K Front Pharmacol. 2022; 13:1005293.

PMID: 36267277 PMC: 9577117. DOI: 10.3389/fphar.2022.1005293.


Exosome Degeneration in Mesenchymal Stem Cells Derived from Patients with Type 1 Diabetes Mellitus.

Horiguchi M, Okada Y, Turudome Y, Ushijima K Int J Mol Sci. 2021; 22(20).

PMID: 34681566 PMC: 8536020. DOI: 10.3390/ijms222010906.

References
1.
Scussolini M, Bauckneht M, Cossu V, Bruno S, Orengo A, Piccioli P . G6Pase location in the endoplasmic reticulum: Implications on compartmental analysis of FDG uptake in cancer cells. Sci Rep. 2019; 9(1):2794. PMC: 6391477. DOI: 10.1038/s41598-019-38973-1. View

2.
Garcia-Prat L, Perdiguero E, Alonso-Martin S, DellOrso S, Ravichandran S, Brooks S . FoxO maintains a genuine muscle stem-cell quiescent state until geriatric age. Nat Cell Biol. 2020; 22(11):1307-1318. DOI: 10.1038/s41556-020-00593-7. View

3.
Cho N, Shaw J, Karuranga S, Huang Y, da Rocha Fernandes J, Ohlrogge A . IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018; 138:271-281. DOI: 10.1016/j.diabres.2018.02.023. View

4.
Tsugata T, Nikoh N, Kin T, Saitoh I, Noguchi Y, Ueki H . Potential Factors for the Differentiation of ESCs/iPSCs Into Insulin-Producing Cells. Cell Med. 2016; 7(2):83-93. PMC: 4733840. DOI: 10.3727/215517914X685178. View

5.
Qi Y, Ma J, Li S, Liu W . Applicability of adipose-derived mesenchymal stem cells in treatment of patients with type 2 diabetes. Stem Cell Res Ther. 2019; 10(1):274. PMC: 6712852. DOI: 10.1186/s13287-019-1362-2. View